Travere Therapeutics, Inc.
pegtibatinase
Classical Homocystinuria (HCU)
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for pegtibatinase in Classical Homocystinuria (HCU) are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“Following further optimization of its manufacturing process in 2025, the Company is on track to restart the pivotal Phase 3 HARMONY Study in the first quarter of 2026.”